Manufacturing, latest filing in July 2026

On June 26, 2026, Mr. Michael Goettler notified Bausch Health Companies Inc. (the "Company") of his decision to resign from the Board of Directors (the "Board"), effective June 30, 2026, in connection with his appointment as President and Chief Executive Officer of Knoa Pharma LLC.

Also stated in this filing

• Mr. Goettler's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

Director Appointment On July 16, 2026, the board of directors (the "Board") of Brownie's Marine Group, Inc., a Florida corporation (the "Company"), appointed Mikkel Pitzner, age 58, to serve as a member of the Board, effective on such date.

Also stated in this filing

• Mr. Pitzner will be paid $4,500 each quarter in common stock of the Company for such Board service.

(d) Election of Director The Board of Directors of Carrier Global Corporation (the "Company") appointed Neil Barua as an independent director, effective July 24, 2026, with a term expiring at the 2027 Annual Meeting of Shareowners.

Also stated in this filing

• The Board also appointed Mr. Barua to the Board's Compensation Committee and Technology & Innovation Committee.

On July 10, 2026, Sam Martin, Senior Vice President and Chief Financial Officer of Celldex Therapeutics, Inc. (the "Company"), notified the Company of his plans to retire effective on or about March 31, 2027.

Also stated in this filing

• Mr. Martin joined the Company in April 2009 and has served as Chief Financial Officer since July 2017.
• The Company has initiated a search for a new Chief Financial Officer.
• To ensure a smooth transition of his responsibilities, Mr. Martin intends to continue to serve the Company as Chief Financial Officer through March 31, 2027 or until such earlier time as his successor begins to serve in such capacity.

On July 23, 2026, Douglas A. Milroy notified the Board of Directors of Donaldson Company, Inc. of his decision to resign from the Board, effective July 31, 2026.

Also stated in this filing

• Mr. Milroy has served on the Board since 2016.

(b) Departure of Director On July 20, 2026, Jennifer Hyman, a member of the Board of Directors (the "Board") of The Est e Lauder Companies Inc. (the "Company"), notified the Company that she will retire from the Board, effective November 16, 2026 (the day before the Company's 2026 Annual Meeting of Stockholders).

Also stated in this filing

• Ms. Hyman, a Class I director, has been a Board member since 2018, and is a member of the Audit Committee and the Nominating and ESG Committee.
• Ms. Hyman's decision to retire from the Board is to shift her focus to new endeavors, and is not due to any disagreements with the Company on any matter relating to the Company's operations, policies, or practices.
• The Company is grateful for her contributions during the time she has served on the Board.

The Tax reimbursement agreement will be null and void if the Merger Agreement is terminated for any reason prior to the Effective Time.

Also stated in this filing

• Also on November 1, 2026, the Lumentum Board approved the Company's entry into a Tax reimbursement agreement with the Company's other named executive officers, as may be necessary or advisable to mitigate the effects of Section 280G of the Code on such executives.

On July 27, 2026, Vincent Retort, Executive Vice President, Global Reliability & Quality of Lumentum Holdings Inc. (the "Company"), informed the Company of his planned retirement from the Company, effective in October 2026.

Also stated in this filing

• Mr. Retort has agreed to provide consulting services to the Company for a two-year term following his retirement (the "Consulting Term").
• In exchange for Mr. Retort's services, his outstanding equity awards will continue to vest during the Consulting Term in accordance with their existing vesting schedules, provided that he remains as a service provider to the Company.

(d) Election of Director On July 20, 2026, the Board of Directors of MSA Safety Incorporated elected Octavio Marquez to the Company's Board of Directors.

Also stated in this filing

• At this time, Mr. Marquez has not been appointed to any Board committees.

On July 19, 2026, Lisa Bollinger, MD, Chief Medical Officer of Polaryx Therapeutics, Inc. (the "Company"), resigned from her position with the Company, effective immediately.

Also stated in this filing

• The Company does not anticipate that Dr. Bollinger's resignation will affect previously disclosed clinical timelines, regulatory plans or development strategy.
• The Company has commenced a search for a successor.

On July 29, 2026, The Procter & Gamble Company (the "Company") announced that Jon R. Moeller, Executive Chairman of the Board, will retire from his position as Executive Chairman and as a member of the Board of Directors ("the Board"), effective July 31, 2026.

Also stated in this filing

• Mr. Moeller will remain with the Company through August 14, 2026, when he will retire from the Company.
• The Company also announced that Shailesh G. Jejurikar, currently President and Chief Executive Officer and a member of the Board, has been appointed Chairman of the Board, in addition to his current responsibilities, effective August 1, 2026, to serve at the pleasure of the Board.
• In addition, the non-employee Directors of the Board reappointed Joseph Jimenez as the Board's independent Lead Director.

In connection with her appointment, Dr. Hannah resigned from the Company's Board of Directors (the "Board"), effective July 1, 2026.

Also stated in this filing

• On July 1, 2026, Rigel Pharmaceuticals, Inc. (the "Company") announced that Alison L. Hannah, M.D. was appointed Executive Vice President and Chief Medical Officer of the Company.
• Dr. Hannah had served as a member of the Board since May 2021.
• Since 2000, Dr. Hannah has served as a consultant to the pharmaceutical and biotechnology industry, directing the development of investigational cancer therapies.
• Prior to her consulting work, Dr. Hannah served as Chief Medical Officer of CytomX Therapeutics and as Senior Medical Director at SUGEN, Inc. Effective June 25, 2026, Lisa Rojkjaer, M.D. ceased serving as Executive Vice President and Chief Medical Officer of the Company and separated from the Company.

On July 22, 2026, the Board of Directors (the "Board") of TransDigm Group Incorporated (the "Company" or "TransDigm") appointed Irina Krasik to the Company's Board of Directors, effective immediately.

Also stated in this filing

• Ms. Krasik has been with Stellex Capital Management since 2021 and serves as a Managing Director.
• Prior to joining Stellex Capital Management, she was a Principal at Bregal Investments and previously spent more than eight years at The Wicks Group in various investment roles.
• Earlier in her career, Ms. Krasik held positions at The Carlyle Group and Merrill Lynch.
• She currently serves on the boards of directors of several privately held companies and brings to the Board extensive experience in mergers and acquisitions, investing, corporate strategy and governance.
• Ms. Krasik holds an M.B.A. from Harvard Business School and a B.S. in Finance from Rutgers University.
• Ms. Krasik has not been appointed to any committees of the Board.

On July 22, 2026, the Board of Directors (the Board ) of United Therapeutics Corporation (the Company ), acting upon the recommendation of its Nominating and Governance Committee, increased the size of the Board to 13 members and appointed Victor Dzau, M.D., to serve as a member of the Board.

Also stated in this filing

• The Board determined that Dr. Dzau will not serve on a Board committee initially.
• These awards were granted on July 22, 2026, in accordance with the Company's standard non-employee director compensation program (the Director Compensation Program ), as described in the Company's definitive proxy statement for its 2026 annual meeting of shareholders, filed with the Securities and Exchange Commission ( SEC ) on April 29, 2026.
• Dr. Dzau will be provided further compensation for his services in accordance with the Director Compensation Program.

On April 24, 2026, Vera Bradley, Inc. (the "Company") announced that long-time board member Carrie Tharp has decided not to stand for re-election at the upcoming 2026 Shareholder Meeting.

Also stated in this filing

• Ms. Tharp's decision to not stand for re-election did not result from any disagreement with the Company concerning any matter relating to its operations, policies, or practices.
• Ms. Tharp joined the Company's Board in 2020 and has served as a member on both the Talent and Compensation Committee, as well as the Audit Committee during her tenure.

Departure of Min Chul Park, Ph.D. On July 8, 2026, Min Chul Park, Ph.D., notified the Board of Directors (the " Board ") of ZyVersa Therapeutics, Inc. (the " Company ") of his intention to resign from his Board positions as an independent director, member of the Compensation Committee of the Board, and member of the Nominating and Corporate Governance Committee of the Board.

Also stated in this filing

• Dr. Park's resignation has been accepted by the Board, effective immediately.
• Dr. Park's resignation was due to personal reasons and not a result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.